Medical Technology · global
Clinical Mass Spectrometry Pushes Trace Detection Further: Waters Launches Xevo TQ Absolute XR IVD System
The new system targets the analysis of low-concentration hormones and toxic substances, claiming up to a fivefold increase in sensitivity and longer tolerance of complex matrices. However, existing data come primarily from manufacturer testing, and clinical laboratories must still complete validation for each individual test.
When testing targets are present only at extremely low concentrations, an instrument’s ability to consistently identify signals in complex samples such as serum and hair may directly limit the range of applications for a testing method. Waters has launched the Xevo TQ Absolute XR IVD tandem quadrupole mass spectrometer, seeking to enter clinical applications including women’s health, cancer assessment, and toxicology analysis with higher sensitivity and a lower maintenance burden.
This MassTrak liquid chromatography–tandem mass spectrometry system integrates the Xevo TQ Absolute XR IVD mass spectrometer with the ACQUITY UPLC I-Class PLUS. Waters says the new model can deliver up to five times greater sensitivity than comparable in vitro diagnostic mass spectrometers, potentially allowing laboratories to use smaller samples and measure analytes that were previously near the detection limit.
Specific applications include the detection of low-concentration estradiol. Such measurements can be used in women’s health and the assessment of hormone-related cancers, but the low-concentration range is susceptible to interference from other molecules and the sample matrix. Another use case is hair toxicology analysis: drugs and their metabolites may leave only trace signals, yet can provide exposure information over a longer time frame.
Beyond signal intensity, routine testing places greater emphasis on whether an instrument can maintain consistency over extended periods. The new system uses the StepWave XR ion guide. The company says its ion ratio can remain stable for up to six times longer than with the previous-generation Xevo TQ Absolute system, with the aim of reducing contamination, signal drift, and maintenance-related downtime caused by matrix components such as phospholipids and salts.
However, both core performance claims require cautious interpretation. The fivefold sensitivity figure comes from Waters’ comparisons with its own Xevo TQ-XS IVD and the SCIEX 6500 IVD; the announcement does not comprehensively present the full testing conditions or performance across different analytes. The sixfold durability figure comes from a controlled experiment using pesticides in fish feed as the matrix and analyzing more than 12,000 samples, and cannot be directly equated with the results of long-term clinical specimen processing.
The system is currently available to order, but the announcement does not specify its approval status in individual markets or its price, nor does it provide independent peer-reviewed research or complete validation data from clinical laboratories. For testing facilities, the IVD designation of the hardware does not mean that every laboratory-developed test has received regulatory recognition. Whether it can truly improve clinical workflows will still depend on each analytical method’s precision, accuracy, interference testing, quality control, and local regulatory requirements.